Document:

CONFIDENTIAL DISCLOSURE AGREEMENT

This  Agreement  is  made  by  and  between   Ophidian   Pharmaceuticals,   Inc.
(hereinafter  "OPHIDIAN"),  a  Delaware  corporation  with  offices at 5445 East
Cheryl  Parkway,   Madison,   WI.,  53711  and  Biosyntech  Ltd.,   (hereinafter
"BIOSYNTECH")  a  Canadian  corporation  with  offices at 475  Boulevard  Armand
Frappier,  Montreal  (Laval) QC, CANADA H7V 4B3. This Agreement will confirm the
mutual  interest of OPHIDIAN and BIOSYNTECH in sharing  certain  information and
providing for protection of that  information.  Each party shall disclose to the
other certain  confidential  business and  technology  information  for the sole
purpose of evaluating a business relationship.

                                    RECITALS

Each  undersigned  party,  intending to be legally bound,  understands  that the
other party (the Disclosing Party) intends to disclose  information  relating to
the Disclosing  Party's  business so that the other party (the Receiving  Party)
may evaluate such information on the following terms and conditions:

1.   Following the full execution of this Agreement, each party will disclose to
     the other party certain of its confidential,  proprietary information,  and
     other  Confidential  Information,   relating  to  pharmaceutical  research,
     development, manufacturing and marketing. Such Confidential Information may
     include,  but is not  necessarily  limited to,  business  concepts,  market
     analysis,  technology,  processes, data, materials, patent applications and
     medical or other applications, except any portion thereof which:

     (a)  at the time of disclosure is in the public domain;
     (b)  after disclosure  becomes part of the public domain,  except by breach
          of this Agreement;
     (c)  was in the  possession of the recipient at the time of disclosure  and
          was not  acquired,  directly or  indirectly,  under an  obligation  of
          confidentiality,   as  established  by  competent   written  evidence;
     (d)  was received by recipient  from a third party who is not,  directly or
          indirectly,  under an obligation for confidentiality to the Disclosing
          Party with respect to such information;
     (e)  is  required  by a  judicial  or  administrative  agency of  competent
          jurisdiction to be disclosed,  after maximum practicable notice by the
          receiving party to the disclosing party; or,
     (f)  was  developed  by or for  the  Recipient  independent  of  disclosure
          hereunder as evidence by Recipient's written records.

2.   The Receiving Party agrees not to use the Confidential Information provided
     by the  Disclosing  Party for any purpose other than the  evaluation of the
     aforementioned  business  relationship.

3.   The  Receiving  Party  agrees  to  limit  distribution  of  and  access  to
     Confidential Information only to employees,  officers, and directors within
     the  Receiving  Party's  immediate  organization  (and  within any  parent,
     subsidiary or affiliated entity) and outside, third party consultants bound
     by confidentiality requirements no less stringent than those contain within
     this  agreement,  and then only to those  individuals who have a legitimate
     "need to know" for the above described evaluation purpose. Each party shall
     take all reasonable steps to ensure that

<PAGE>

such  employees,  whether  during or after their  employment  with the Receiving
party,  shall keep the Disclosing Party's  Confidential  Information secret from
other entities.

4.   Receipt and  evaluation of  information  shall be limited to a one (1) year
     period  following  the date of full  execution  of this  Agreement,  unless
     extended by written agreement signed by the parties.  Upon thirty (30) days
     written  notice  to the  other  party,  either  party  may  terminate  this
     agreement;  provided,  however,  that all obligations of nondisclosure  and
     non-use,  as well as those  provisions which by their nature should survive
     termination, shall so survive for a period of three (3) years from the date
     hereof.

5.   The  existence,  terms,  nature,  or subject  matter of this  Agreement are
     confidential and shall be treated as Confidential  Information  pursuant to
     the terms of this Agreement.

6    Confidential  Information  received  from  the  Disclosing  Party  and  any
     developments  materially  derived  therefrom  are and shall remain the sole
     property  of the  Disclosing  Party.  Nothing  herein  shall be  deemed  to
     constitute  by  implication  or  otherwise  the  license  or  grant  to the
     Receiving  Party by the Disclosing  party,  except as  anticipated  for the
     purpose  of  this  Agreement,  of any  intellectual  property  right  to or
     interest in the  Disclosing  Party's  information  and/or any  information,
     technology  and/or  products  materially  derived or  developed  therefrom,
     notwithstanding  the  exceptions  set  forth in  Paragraph  1  herein.  The
     Receiving Party shall not use, develop, disclose to any third party, and/or
     commercials e any of the foregoing  without the Disclosing  Party s written
     consent.  No  agency  or  partnership   relationship  is  created  by  this
     Agreement; no warranties, right to use or fitness for any purpose or of any
     other kind are made by either  Disclosing  Party; and it is understood that
     neither party has any obligation to enter into any further  agreements with
     the other related to any business or any other matter.

7.   Nothing in this Agreement  shall be deemed,  by implication or otherwise to
     convey  to the  Receiving  Party any  rights  under  any  patents,  patents
     application, copyrights, trademarks, trade secrets, inventions or any other
     intellectual   property  in  which  the  Disclosing  Party  has  rights  or
     interests,  nor shall this  Agreement be deemed a commitment of any kind by
     either the Receiving Party or the Disclosing Party to enter in to an future
     agreement with the other.

8.   Each  Receiving  Party  shall  exercise  due  care--not  less than the care
     accorded  its  own  valuable  Confidential   Information--to   prevent  the
     unauthorized  disclosure  of  Confidential  Information  received  from the
     Disclosing  Party  hereunder,  or  its  use  for  any  purpose  other  than
     evaluation and consultation with the Disclosing party.

9.   Each party represents that it has the right to make disclosures  under this
     Agreement;  that  it  will  not  disclose  to  the  other  any  information
     confidential  to any third party;  and that the terms of this Agreement are
     not inconsistent with other  contractual  and/or other legal obligations it
     may  have,  or with  the  policies  of any  institution  with  which  it is
     associated.

10.  Upon termination of either mutual evaluations or business relations between
     parties,  or within  thirty (30) days,  if  otherwise  requested  by either
     parry,  each Receiving  Party shall,  upon written return to the Disclosing
     Party all written or other physical embodiments of Confidential Information
     (including tangible materials,  unless requested by the Disclosing Party to
     properly  destroy or dispose  thereof),  together  with all full or partial
     copies  thereof,  as shall  then be in the  Receiving  Party's  possession,
     except  that each party may retain one  complete  record  copy of the other
     party's  Confidential  Information  for  archival  purposes  and to  assure
     compliance with this Agreement.

11.  This Agreement  shall be governed and construed in accordance with the laws
     of the State of  Delaware,  United  States  of  America  without  regard to
     principles of conflict of laws, and this original  English language version
     of the Agreement  shall be controlling in all respects.  In the event legal
     action  becomes  necessary for the  enforcement or  interpretation  of this
     Agreement  such  action  will be brought in the US  District  Court for the
     Western District of Wisconsin, and the parties will submit to the venue and
     jurisdiction of said courts.

12.  No  course  of  conduct  or  dealing  between  the  parties  shall act as a
     modification  or waiver of any  provision  of this  Agreement,  unless such
     modification  or  waivers  are-  contained  in  writing  and signed by duly
     authorized representative of each party

Ophidian Pharmaceuticals, Inc.                    BIOSYNTECH LTD.

By:      /s/ Douglas C. Stafford, Ph.D.       By:  /s/ Francois Binette
         ------------------------------            --------------------
Name:    Douglas C. Stafford, Ph.D.           Name:   Francois Binette

Title:      President and CEO                 Title:  Vice President R&D

Date:       12 August 1999                    Date:       8/16/99
         ------------------------------              ---------------------------Biological Materials Transfer Agreement

This  Agreement  by and  between  OPHIDIAN  PHARMACEUTICALS,  INC.  (hereinafter
OPHIDIAN),  a  Delaware  corporation,  having a  principal  address at 5445 East
Cheryl   Parkway,   Madison,   WI  53711  and  BIOSYNTECH   LTD.,   (hereinafter
"BIOSYNTECH")  a  Canadian  corporation  with  offices at 475  Boulevard  Armand
Frappier, Montreal (Laval) QC, CANADA H7V 4B3 and shall govern the conditions of
transfer of materials and the confidential disclosure of proprietary information
to and from the aforementioned parties.

Whereas  BIOSYNTECH  and  OPHIDIAN  desire  to  receive  certain  Materials  and
Information from the other party to this agreement for scientific and commercial
evaluation;
Whereas  OPHIDIAN  and  BIOSYNTECH  are  willing to provide  the  Materials  and
Information described herein;

Now, therefore OPHIDIAN and BIOSYNTECH agree as follows:

     1.   "Materials"   shall  mean  proprietary   original   materials  of  the
          respective parties;

     2.   "Information"   shall  mean,   subject  to  paragraph  4  below,   all
          information relating to the Materials;

     3    Materials  shall remain the sole property of the party providing them.
          The Providing Party shall retain all  intellectual  property rights in
          Materials  and  Information.  The  Receiving  Party shall not transfer
          materials  and materials  derived from  Materials to anyone other than
          its  employees.  Only those  employees of the  Receiving  Party with a
          legitimate   need  for  access  will  have  access  to   Materials  or
          Information.  Materials  may  not  be  transferred  or  taken  by  the
          Receiving  Party to another  institution or company  without the prior
          written consent of the Providing Party.  Materials will not be sold to
          third parties and shall not be used for research, testing or treatment
          involving human subjects or for making any clinical decisions relating
          to human diagnosis or care.

     4.   Information  generated  during this material  transfer and  evaluation
          shall be retained in  confidence  by both  parties for three (3) years
          and shall not be disclosed to third parties,  unless the  information:
          a) at the time of  disclosure is in the public  domain;  b) disclosure
          becomes part of the public domain, except by breach of this Agreement;
          c) was in the  possession of the recipient of the  information  at the
          time of disclosure as established by competent  written  evidence;  d)
          was received  from a third party who is not,  directly or  indirectly,
          under  an   obligation  of   confidentiality   with  respect  to  such
          information;   or  e)  is  approved  for  public  release  by  written
          authorization of the other party to this agreement.

      5   The  Receiving  Party agrees to use Materials or  Information  and the
          results of Receiving  Party's  evaluation  of Materials to; a) examine
          the  possibility  of entering  into a business  relationship  with the
          Providing Party, and not for any other commercial purposes.

     6.   OPHIDIAN  and  BIOSYNTECH  agree that  nothing  herein shall create or
          imply any obligation to enter into any other agreement.

     7.   Information  or materials  received from the  Providing  Party and any
          developments  materially  derived  therefrom  are and shall remain the
          sole property of the Providing  Party.  Nothing herein shall be deemed
          to constitute by  implication or otherwise the license or grant to the
          Receiving  Party by the Providing Party of any  intellectual  property
          right to or interest in the Providing Party's  information  and/or any
          information,   technology  and/or  products   materially   derived  or

<PAGE>
          developed  therefrom,  except as the parties may subsequently agree in
          writing.  The Receiving Party shall not use, develop,  disclose to any
          third party,  and/or  commercialize  any of the foregoing  without the
          Providing   Party's   written   consent.   No  agency  or  partnership
          relationship is created by this  Agreement;  no warranties are made by
          the  Providing  Party or right to use or fitness for any purpose or of
          any  other  kind;  and it is  understood  that  neither  party has any
          obligation to enter into any further agreements with the other related
          to any Technology or any other matter.

     8.   The Materials to be delivered by the Providing  Party to the Receiving
          Party  are to be used in a safe  manner  and in  accordance  with  all
          applicable  governmental  rules and regulations.  They are provided by
          the   Providing   Party  "AS  IS."  THE   PROVIDING   PARTY  MAKES  NO
          REPRESENTATIONS  AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS
          OR IMPLIED,  WITH RESPECT TO THE MATERIALS AND EXPRESSLY DISCLAIMS ALL
          IMPLIED WARRANTIES OF MERCHANTABILITY  AND OF FITNESS FOR A PARTICULAR
          PURPOSE OR USE. THE PROVIDING  PARTY  DISCLAIMS ALL  WARRANTIES OF NON
          INFRINGEMENT  WITH  RESPECT  TO ANY  THIRD  PARTY  RIGHTS  AND  TITLE,
          INCLUDING PATENT RIGHTS, IN THE MATERIALS.

     9.   Except to the extent  specifically  precluded by applicable federal or
          state law, the  Receiving  Party agrees to defend,  indemnify and hold
          the Providing Party and its directors, trustees, appointees, employees
          and agents harmless from any claims,  liabilities,  damages and losses
          that  might  arise  as a  result  of the  Receiving  Party  use of the
          Providing Party Materials or the Providing  Party  Information.  Where
          such  indemnity  is  precluded,   the  Receiving  Party  assumes  sole
          responsibility  for any claims,  liabilities,  damages and losses that
          might arise as result of the Receiving Party use of the Materials.

     10.  Upon conclusion of the evaluation  using the Providing Party Materials
          or upon request by the Providing  Party, the Receiving Party agrees to
          discontinue  use of the Providing Party Materials and will arrange for
          the return to the  Providing  Party or for the lawful  disposal of all
          unused Providing Party Materials, as elected by the Providing Party.

     11.  This Agreement  shall be governed and construed in accordance with the
          laws of the State of Delaware  without  regard or giving effect to its
          principles of conflict of laws. This Agreement  constitutes the entire
          agreement and  understanding  of the parties and  supersedes any prior
          agreements  or  understandings  relating to the subject  matter hereof
          with the exception of the  Confidentiality  Agreement  dated 12 August
          1999 between the  aforementioned  parties.  This  agreement may not be
          modified  except by a written  instrument  signed by all  parties.  No
          provision  or  benefit  of this  agreement  may be  waived,  except by
          Written instrument duly executed by the party or parties to be charged
          therewith.

        /S/ Francois Binette  Date 8/16/99 /S/ Douglas C. Stafford Date: 8/12/99
        --------------------  ------------ ----------------------- -------------
          Francois Binette                 Douglas C. Stafford
          Vice-President R&D               President and CEO
          Biosyntech Ltd.                  OPHIDIAN Pharmaceuticals, Inc.
          475 Blvd. Armand-Frappier        5445 East Cheryl Parkway
          LAVAL. QC.                       Madison, WI 53711
          CANADA H70-4B3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}]]